Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | ALPI | P09923 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24976330 | 0.84 | LTA4H (0.46) | LTA4HSIGMAR1CXCR4CYP3A4 | |
| SCHEMBL24975784 | 0.84 | LTA4H (0.46) | LTA4HSIGMAR1CXCR4CYP3A4 | |
| SCHEMBL11266772 | 0.81 | LTA4H (0.48) | LTA4HSIGMAR1CXCR4L3MBTL1ALDH1A1 | |
| SCHEMBL3881484 | 0.80 | DRD2 (0.48) | LTA4HSIGMAR1ALDH1A1KDM4EMAPT | |
| SCHEMBL3881487 | 0.80 | DRD2 (0.48) | LTA4HSIGMAR1ALDH1A1KDM4EMAPT | |
| SCHEMBL30833195 | 0.80 | DRD2 (0.48) | LTA4HSIGMAR1ALDH1A1KDM4EMAPT | |
| SCHEMBL11094109 | 0.80 | LTA4H (0.58) | LTA4HCXCR4L3MBTL1ALDH1A1CYP2D6 | |
| SCHEMBL30833222 | 0.79 | DRD2 (0.51) | LTA4HMAPT | |
| SCHEMBL3880873 | 0.79 | DRD2 (0.51) | LTA4HMAPT | |
| SCHEMBL3880869 | 0.79 | DRD2 (0.51) | LTA4HMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456192-B2 | 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2008-11-25 | — | — | US | disclosed |
| EP-1440075-B1 | NOVEL 3BETA-AMINO AZABICYCLOOCTANE HETEROAROMATIC AMIDE DERIVATIVES, PREPARATION METHOD AND THERAPEUTIC USES THEREOF | PF MEDICAMENT (FR) | 2005-06-08 | — | — | EP | disclosed |
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | PIERRE FABRE MEDICAMENT (FR) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080085-A1 | Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof | AOC3, MAOB, AOC1 | LTA4H 2910/4885SIGMAR1 153/4885CXCR4 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.